Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants

Ongoing emergence of SARS-CoV-2 Omicron subvariants and their rapid worldwide spread pose a threat to public health. From November 2022 to February 2023, newly emerged Omicron subvariants, including BQ.1.1, BF.7, BA.5.2, XBB.1, XBB.1.5, and BN.1.9, became prevalent global strains (>5% global prev...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Junhyung, Shin, Younmin, Yang, Jeong-Sun, Kim, Jun Won, Kim, Kyung-Chang, Lee, Joo-Yeon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10118056/
https://www.ncbi.nlm.nih.gov/pubmed/37086978
http://dx.doi.org/10.1016/j.antiviral.2023.105609

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10118056/
https://www.ncbi.nlm.nih.gov/pubmed/37086978
http://dx.doi.org/10.1016/j.antiviral.2023.105609

Ejemplares similares